Literature DB >> 23540946

Is there different correlation with prognostic factors between "non-mass" and "mass" type invasive ductal breast cancers?

Lei Jiang1, Yiming Zhou, Zheng Wang, Xu Lu, Min Chen, Cheng Zhou.   

Abstract

PURPOSE: To investigate the association between non-mass type breast cancer and common clinical-pathological prognostic factors, compared with mass type breast cancer.
MATERIALS AND METHODS: After institutional review board approval, retrospective blind review of contrast-enhanced breast MRI was carried out for 88 histologically proven breast invasive ductal carcinoma (IDC) patients, presenting from January 2008 to December 2011. Two radiologists assessed the images of each lesion for the morphologic enhancement type [mass enhancement or non-mass-like enhancement (NMLE)] and the distribution/internal enhancement of NMLE. Two pathologists evaluated the histological grade of IDC, presence or absence of ductal carcinoma in situ (DCIS), lymph node status, presence or absence of vascular invasion, and expression status of estrogen receptor (ER)/progesterone receptor (PR)/HER-2/p53 tumor suppressor gene (p53)/Ki-67. Inter-observer agreement was assessed with kappa test. Chi-square test and Spearman rank correlation were performed to explore the associations of morphologic enhancement type with the age, lesion size and the above pathological prognostic factors
RESULTS: Inter-observer agreement was excellent, with kappa>0.75. Morphologic enhancement type was significantly correlated with age (P=0.02), with NMLE more commonly seen in women less than 50 y/o. The size of NMLE was larger than that of mass and, with the increase of lesion size, proportion of NMLE among the cases increased (P=0.001). NMLE was also significantly correlated with low histologic grade of IDC (P=0.003) and presence of DCIS (P<0.001). There was no significant correlation between morphologic enhancement type and lymph node status, vascular invasion, ER/PR/HER-2/p53/Ki-67 status. The histological grade was higher in clumped enhancement than non-clumped (P=0.011). There was no correlation between enhancement distribution and prognostic factors
CONCLUSIONS: Non-mass type breast cancer may not necessarily have worse prognosis than the mass type, due to lower histological grade and closely related to DCIS component, although it may has larger tumor size. Clumped enhancement may have worse prognosis than non-clumped enhancement.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Invasive ductal carcinoma; MR imaging; Mass; Non-mass-like enhancement; Prognosis

Mesh:

Substances:

Year:  2013        PMID: 23540946     DOI: 10.1016/j.ejrad.2013.03.006

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  4 in total

1.  High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.

Authors:  Abdelbaset Buhmeida; Ashraf Dallol; Adnan Merdad; Jaudah Al-Maghrabi; Mamdooh A Gari; Muhammad M Abu-Elmagd; Adeel G Chaudhary; Adel M Abuzenadah; Taoufik Nedjadi; Eramah Ermiah; Fatima Al-Thubaity; Mohammed H Al-Qahtani
Journal:  Tumour Biol       Date:  2013-11-19

Review 2.  Magnetic resonance imaging in the evaluation of pathologic nipple discharge: indications and imaging findings.

Authors:  Naziya Samreen; Laura B Madsen; Celin Chacko; Samantha L Heller
Journal:  Br J Radiol       Date:  2021-02-05       Impact factor: 3.039

Review 3.  The potential of predictive and prognostic breast MRI (P2-bMRI).

Authors:  Francesco Sardanelli; Pascal A T Baltzer; Matthias Dietzel; Rubina Manuela Trimboli; Moreno Zanardo; Rüdiger Schultz-Wendtland; Michael Uder; Paola Clauser
Journal:  Eur Radiol Exp       Date:  2022-08-22

4.  Decreased expression of C10orf10 and its prognostic significance in human breast cancer.

Authors:  Junjiang Deng; Yan Dong; Chong Li; Wenwei Zuo; Gang Meng; Chengping Xu; Jianjun Li
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.